U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

About this resource:

Non-Systematic Review

Source: Centers for Disease Control and Prevention

Last Reviewed: May 2022

Workgroups: Immunization and Infectious Diseases Workgroup, Older Adults Workgroup

This report updates the Advisory Committee on Immunization Practices’ (ACIP) recommendation for pneumococcal vaccination to simplify recommendations across age and risk groups. 

Previously, the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) were recommended for adults. 

With this update, ACIP recommends the 15-valent PCV (PCV15) or the 20-valent PCV (PCV20) for:

  • Adults age 65 years or older who haven’t previously gotten a pneumococcal vaccine
  • Adults age 19 to 64 years with certain underlying health conditions

When PCV15 is used, it should be followed by a dose of PPSV23 about 1 year later.

Read more about this resource

Objectives related to this resource (1)

Reduce the rate of hospital admissions for pneumonia among older adults — OA‑06
Baseline only

Suggested Citation

1.

Kobayashi M, Farrar JL, Gierke R, et al. (2022). Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. Retrieved from https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm.